Innate Pharma S.A. Announced earnings results for the half year ended June 30, 2021. For the half year, the company announced total revenue was EUR 15.686 million compared to EUR 36.745 million a year ago. Operating loss was EUR 25.428 million compared to EUR 8.348 million a year ago. Net loss was EUR 23.719 million compared to EUR 10.334 million a year ago. Basic loss per share from continuing operations was EUR 0.3 compared to EUR 0.13 a year ago.